Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma By Ogkologos - July 2, 2025 277 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DESTINY-Gastric04 study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Man Born Without Legs Proves He’s Greater Than Any Obstacle He’s... December 5, 2021 Science Surgery: ‘Can cancers develop in the heart?’ March 30, 2021 After Saving Thousands of Dogs, Tragedy Strikes Famed Rescue Family January 4, 2022 Promising Signal of Efficacy for Adjuvant Nivolumab in Patients with Completely... July 19, 2023 Load more HOT NEWS Asciminib Shows Superior Efficacy Over Investigator-Selected TKIs and Imatinib in Patients... ESMO Gastrointestinal Cancers Congress 2024 Munich, Germany, 26-29 June First-Line 177Lu-Dotatate Plus Octreotide LAR Significantly Extends PFS in Patients with... EMA Recommends Extension of Therapeutic Indications for Trastuzumab Deruxtecan
